NCT07839884
A Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of Time
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 5 more changesShow less
- Trial sites expanded: 0 → 3 locations
- Start date changed from estimate of Sep 21, 2026 to Oct 14, 2026
- Primary and study completion dates: May 12, 2034 to Apr 21, 2034
- Secondary endpoints: 28 to 24
- Study description shortened, about 49 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Number of Participants With Treatment-Emergent Adverse Events During Treatment Period 1 (TP1)
Timeframe: Up to 60 weeks
Number of Participants With Treatment-Emergent Serious Adverse Events During Treatment Period 1
Timeframe: Up to 60 weeks
Number of Participants With Treatment-Emergent Adverse Events Leading to Permanent Discontinuation of Study Intervention During Treatment Period 1
Timeframe: Up to 60 weeks
Number of Participants With Clinically Significant Laboratory Abnormalities During Treatment Period 1
Timeframe: Up to 60 weeks
Secondary (24)
Annualized Rate of Moderate or Severe COPD Exacerbations During Treatment Period 1
Annualized Rate of Severe COPD Exacerbations During Treatment Period 1
Annualized Rate of COPD Exacerbations Requiring an Emergency Department Visit and/or Hospitalization During Treatment Period 1
Cumulative Number of Moderate or Severe COPD Exacerbations During Treatment Period 1
Cumulative Number of Severe COPD Exacerbations During Treatment Period 1
Show 19 moreShow less
Time to First Moderate or Severe COPD Exacerbation During Treatment Period 1
Change From Parent-Study Baseline in Pre- and Post-Bronchodilator Lung Function During Treatment Period 1
Change From Parent-Study Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score During Treatment Period 1
Change From Parent-Study Baseline in COPD Assessment Test (CAT) Total Score During Treatment Period 1
Change From Parent-Study Baseline in Weekly Use of Short-Acting Bronchodilator Medication During Treatment Period 1
Percentage of Participants Achieving at Least a 4-Point Improvement From Parent-Study Baseline in SGRQ Total Score During Treatment Period 1
Percentage of Participants Achieving at Least a 2-Point Improvement From Parent-Study Baseline in CAT Total Score During Treatment Period 1
Annualized Rate of Moderate or Severe COPD Exacerbations Through End of Study
Annualized Rate of Severe COPD Exacerbations Through End of Study
Annualized Rate of COPD Exacerbations Requiring an Emergency Department Visit and/or Hospitalization Through End of Study
Cumulative Number of Moderate or Severe COPD Exacerbations Through End of Study
Cumulative Number of Severe COPD Exacerbations Through End of Study
Time to First Moderate or Severe COPD Exacerbation Through End of Study
Change From Parent-Study Baseline in Pre- and Post-Bronchodilator Lung Function Through End of Study
Change From Parent-Study Baseline in SGRQ Total Score After Week 52
Change from the parent-study baseline in CAT total score at each scheduled assessment after Week 52 of TP1
Change From Parent-Study Baseline in Weekly Use of Short-Acting Bronchodilator Medication After Week 52
Percentage of Participants Achieving at Least a 4-Point Improvement From Parent-Study Baseline in SGRQ Total Score After Week 52
Percentage of Participants Achieving at Least a 2-Point Improvement From Parent-Study Baseline in CAT Total Score After Week 52
Arms and interventions
Tilrekimig (PF-07275315)Experimental
Tilrekimig (PF-07275315) subcutaneous injection (sc)
Drugs: Tilrekimig
Sites
3 sites in 1 country